BLTE — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

2.54

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

2.88

Price

152.93

Target Price

211.5

Analyst Recom

Performance Q

-1.89

Upside

-152.9%

Beta

-1.15

Ticker: BLTE

14 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	BLTE	179.35	N/A	N/A	0
2026-03-10	BLTE	174.33	N/A	N/A	0
2026-03-11	BLTE	173.65	N/A	N/A	0
2026-03-12	BLTE	169.14	N/A	N/A	0
2026-03-13	BLTE	169.55	N/A	N/A	0
2026-03-17	BLTE	161.93	N/A	N/A	0
2026-03-18	BLTE	162.01	N/A	N/A	0
2026-03-19	BLTE	158.92	N/A	N/A	0
2026-03-20	BLTE	155	N/A	N/A	0
2026-03-23	BLTE	151.02	N/A	N/A	0
2026-03-24	BLTE	150.6	N/A	N/A	0
2026-03-25	BLTE	154.98	N/A	N/A	0
2026-03-26	BLTE	148.81	N/A	N/A	0
2026-03-27	BLTE	152.47	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

14 items 1 of 1

14 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	BLTE	179.61	-43.2	-	-2.09
2026-03-10	BLTE	174.26	-43.2	-	-2.09
2026-03-11	BLTE	173.69	-43.2	-	-2.09
2026-03-12	BLTE	169.12	-43.2	-	-2.09
2026-03-13	BLTE	164.13	-43.2	-	-2.09
2026-03-17	BLTE	162.00	-43.2	-	-2.09
2026-03-18	BLTE	161.73	-43.2	-	-2.09
2026-03-19	BLTE	159.22	-43.2	-	-2.09
2026-03-20	BLTE	154.94	-43.2	-	-2.09
2026-03-23	BLTE	150.48	-43.2	-	-2.09
2026-03-24	BLTE	150.68	-43.2	-	-2.09
2026-03-25	BLTE	155.04	-43.2	-	-2.09
2026-03-26	BLTE	148.83	-43.2	-	-2.09
2026-03-27	BLTE	152.93	-43.2	-	-2.09
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

14 items 1 of 1

14 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	BLTE	0.00	5.57	1.75
2026-03-10	BLTE	0.00	5.57	1.75
2026-03-11	BLTE	0.00	5.57	2.03
2026-03-12	BLTE	0.00	5.57	2.03
2026-03-13	BLTE	0.00	5.57	2.03
2026-03-17	BLTE	0.00	5.57	2.03
2026-03-18	BLTE	0.00	5.57	2.03
2026-03-19	BLTE	0.00	5.57	2.03
2026-03-20	BLTE	0.00	5.57	2.03
2026-03-23	BLTE	0.00	5.55	2.03
2026-03-24	BLTE	0.00	5.55	2.03
2026-03-25	BLTE	0.00	5.55	2.54
2026-03-26	BLTE	0.00	5.55	2.54
2026-03-27	BLTE	0.00	5.55	2.54
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

14 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.64

Avg. EPS Est. Next Quarter

-0.67

Insider Transactions

Institutional Transactions

5.55

Beta

-1.15

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

23.5

Max Drawdown 5-Year %

Target Price

211.5

P/E

Forward P/E

117.43

PEG

P/S

P/B

7.76

P/Free Cash Flow

EPS

-2.3

Average EPS Est. Cur. Y

-2.09

EPS Next Y. (Est.)

0.79

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.52

Return on Equity vs Sector %

-50.1

Return on Equity vs Industry %

-33.8

EPS 1 7Days Diff

-0.9

EPS 1 30Days Diff

-0.85

EBIT Estimation

◆ BLTE Healthcare

$152.07

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

2/20

Pullback

21/25

Volume

11/15

Valuation

11/20

TP/AR

2/10

Options

0/10

RSI

37.2

Range 1M

12.4%

Sup Dist

3.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

12/30

Estimates

0/20

Inst/Vol

6/15

Options

0/10

EPS Yr

7.3%

EPS NY

160.4%

52W%

68.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🔴 SELL -47.3% upside

Quality

2/30

Valuation

0/30

Growth

7/25

Stability

7/10

LT Trend

1/5

Upside

-47.3%

Quality

Belite Bio, Inc

Sector: Healthcare

Industry: Biotechnology

Employees:

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

BLTE

Latest News

—

Caricamento notizie per BLTE…

stock quote shares BLTE – Belite Bio Inc ADR Stock Price stock today

news today BLTE – Belite Bio Inc ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch BLTE – Belite Bio Inc ADR yahoo finance google finance

stock history BLTE – Belite Bio Inc ADR invest stock market

stock prices BLTE premarket after hours

ticker BLTE fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: BLTE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y